Brentuximab vedotin
Adcetris (brentuximab vedotin) is an antibody pharmaceutical. Brentuximab vedotin was first approved as Adcetris on 2011-08-19. It is used to treat hodgkin disease and large-cell lymphoma immunoblastic in the USA. It has been approved in Europe to treat hodgkin disease and non-hodgkin lymphoma. The pharmaceutical is active against tumor necrosis factor receptor superfamily member 8.
| Trade Name | Adcetris |
|---|---|
| Common Name | Brentuximab vedotin |
| Indication | hodgkin disease, large-cell lymphoma immunoblastic, non-hodgkin lymphoma |
| Drug Class | Synthetic analogs of the dolastatin series; monoclonal antibodies: chimeric, tumors as target |
